GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Amyris Inc (OTCPK:AMRSQ) » Definitions » EBIT

Amyris (Amyris) EBIT

: $-598.5 Mil (TTM As of Mar. 2023)
View and export this data going back to 2010. Start your Free Trial

Amyris's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2023 was $-189.7 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2023 was $-598.5 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Amyris's annualized ROC % for the quarter that ended in Mar. 2023 was -71.14%. Amyris's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was -274.33%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Amyris's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was -58.46%.


Amyris EBIT Historical Data

The historical data trend for Amyris's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amyris Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -187.53 -183.47 -275.90 -246.71 -513.89

Amyris Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -105.00 -103.93 -160.83 -144.13 -189.65

Competitive Comparison

For the Specialty Chemicals subindustry, Amyris's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amyris EV-to-EBIT Distribution

For the Chemicals industry and Basic Materials sector, Amyris's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Amyris's EV-to-EBIT falls into.



Amyris EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-598.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amyris  (OTCPK:AMRSQ) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Amyris's annualized ROC % for the quarter that ended in Mar. 2023 is calculated as:

ROC % (Q: Mar. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2022 ) + Invested Capital (Q: Mar. 2023 ))/ count )
=-470.532 * ( 1 - 0.42% )/( (665.841 + 651.38)/ 2 )
=-468.5557656/658.6105
=-71.14 %

where

Invested Capital(Q: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=824.932 - 239.877 - ( 64.437 - max(0, 387.147 - 306.361+64.437))
=665.841

Invested Capital(Q: Mar. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=679.679 - 255.432 - ( 11.245 - max(0, 470.794 - 243.661+11.245))
=651.38

Note: The Operating Income data used here is four times the quarterly (Mar. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Amyris's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2022  Q: Mar. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-758.612/( ( (272.984 + max(-67.338, 0)) + (280.072 + max(-93.565, 0)) )/ 2 )
=-758.612/( ( 272.984 + 280.072 )/ 2 )
=-758.612/276.528
=-274.33 %

where Working Capital is:

Working Capital(Q: Dec. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(52.383 + 111.88 + 32.476) - (239.877 + 0.026 + 24.174)
=-67.338

Working Capital(Q: Mar. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(47.678 + 109.021 + 30.904) - (255.432 + 0.033 + 25.703)
=-93.565

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Amyris's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2023 )
=-598.544/1023.786
=-58.46 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amyris EBIT Related Terms

Thank you for viewing the detailed overview of Amyris's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Amyris (Amyris) Business Description

Traded in Other Exchanges
N/A
Address
5885 Hollis Street, Suite 100, Emeryville, CA, USA, 94608
Amyris Inc is an industrial biotechnology company. It is engaged in the engineering, manufacturing, and sales of products in a variety of consumer and industrial markets, including cosmetics, flavors and fragrances, solvents and cleaners, polymers, lubricants, healthcare products, and fuels. The business operations are spread across the world with the majority of the revenues generated in the United States. The company generates revenue from the sale of renewable products, licenses of and royalties from intellectual property, and grants, and collaborative research and development services.
Executives
J. Scott White director 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Philip J. Gund officer: Chief Restructuring Officer C/O SUNEDISON, INC., 13736 RIVERPORT DR., MARYLAND HEIGHTS MO 63043
M. Freddie Reiss director 2951 28TH STREET, SUITE 1000, SANTA MONICA CA 90405
Hermanus Kieftenbeld officer: Chief Financial Officer 259 PROSPECT PLAINS RD., BLDG A, CRANBURY NJ 08512
Eduardo Alvarez officer: Chief Operating Officer AMYRIS, INC., 5885 HOLLIS STREET, SUITE 100, EMERYVILLE CA 94608
Elizabeth E. Dreyer officer: CHIEF ACCOUNTING OFFICER EDGEWELL PERSONAL CARE, 1350 TIMBERLAKE MANOR PARKWAY, CHESTERFIELD MO 63017
Frank Kung director C/O VIVO CAPITAL, 505, PALO ALTO CA 94301
Nicole Kelsey officer: General Counsel and Secretary AMYRIS, INC., 5885 HOLLIS STREET, SUITE 100, EMERYVILLE CA 94608
John Melo director, officer: President and CEO C/O AMYRIS, INC., 5885 HOLLIS ST., SUITE 100, EMERYVILLE CA 94608
Anthony Hughes officer: Chief Accounting Officer 5885 HOLLIS STREET, SUITE 100, EMERYVILLE CA 94608
Ana Dutra director C/O KORN/FERRY INTERNATIONAL, 1900 AVENUE OF THE STARS, SUITE 2600, LOS ANGELES CA 90067
James F Mccann director ONE OLD COUNTRY ROAD, SUITE 500, CARLE PLACE NY 11514
Ryan Panchadsaram director 5885 HOLLIS ST., SUITE 100, EMERYVILLE CA 94608
L John Doerr director, 10 percent owner C/O KLEINER PERKINS CAUFIELD & BYERS, 2750 SAND HILL ROAD, MENLO PARK CA 94025
Julie Washington director C/O JAMBA, INC., 6475 CHRISTIE AVENUE, NO. 150, EMERYVILLE CA 94608